Bausch & Lomb licenses rPlasmin from Talecris

By Elaine Rigoli

Tampa, Fla., Aug. 29 - Talecris Biotherapeutics has granted an exclusive worldwide license to Bausch & Lomb for recombinant Plasmin technology for use in ophthalmology.

The companies will co-develop rPlasmin, a recombinant derivative of the human blood component plasmin, which Bausch & Lomb believes may have potential for use in developing novel therapies for ocular conditions.

Talecris is pursuing development of the technology in non-ocular applications, specifically to dissolve blood clots in veins and arteries.

Bausch & Lomb said it is enrolling patients in early stage clinical trials to evaluate Plasmin's therapeutic potential to relieve retinal traction.

Under the agreement, Bausch & Lomb will be responsible for development of rPlasmin for use in ophthalmology. Bausch & Lomb will make milestone payments based on the development and registration progress and pay ongoing royalties based on product sales.

Talecris is a biotherapeutic and biotechnology company based in Research Triangle Park, N.C.

Bausch & Lomb is an eye-health company located in Rochester, N.Y.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.